适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 81
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
IMA401-101 – Treatment of patients with solid tumors with IMA401 TCER®, a bispecific T-cell receptor (Phase I trial)Solid TumorsMedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2023-506854-19-00Immatics Biotechnologies GmbH50
尚未招募
不适用
Premarket study to assess safety and performance of the Orion Magnetic Localization System for breast cancerBreast CancerNL-OMON24152Sirius Medical Systems B.V.30
招募中
1 期
Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic DermatitisAtopic DermatitisCTIS2022-502997-18-00Bristol-Myers Squibb Services Unlimited Company64
进行中（未招募）
不适用
/AMedDRA version: 14.1Level: LLTClassification code 10062357Term: SIRSSystem Organ Class: 10018065 - General disorders and administration site conditionsMedDRA version: 14.1Level: LLTClassification code 10040072Term: SepticaemiaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-000748-81-FIJohanna Hästbacka
招募中
1 期
Study to evaluate the safety of MAQ-001 as monotherapy and combination therapy in patients with advanced cancersAdvanced cancer histologies for which immune checkpoint blockade is an approved treatment option, such as: Metastatic melanoma, Lung cancer, Renal Cell Carcinoma (RCC), Hodgkin’s lymphoma, Microsatellite Instability (MSI)-high colon cancer, Hepatocellular Carcinoma (HCC), and Gastric cancer.CTIS2023-507774-41-00MabQuest S.A.30